Science
Neurocrine Biosciences and the delicate balance of benefit and When it comes to rare disease treatments, patients often confront a difficult risk-benefit calculus.
When it comes to rare disease treatments, patients often confront a difficult risk-benefit calculus.
Dr. Kai NakamuraChief Science CorrespondentPublished Aug 13, 2026 at 7:53 AM EDT · 1 min read
Neurocrine Biosciences and the delicate balance of benefit and When it comes to rare disease treatments, patients often confront a difficult risk-benefit calculus. When it comes to rare disease treatments, patients often confront a difficult risk-benefit calculus.
Continue reading
Latest →Corrections, sourcing and article labels are part of the publication record. See our editorial standards.